|
Influenza A virus A/South Australia/55/2014 (H3N2) antigen (MDCK cell derived, propiolactone inactivated)
|
DB11001 |
[A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen". This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. Upon re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it was previously exposed to.
There are two basic types of vaccines available: inactivated influenza vaccine (IIV) and live attenuated influenza vaccine (LAIV). Inactivated vaccines contain a virus particle that has been grown in media and then subsequently killed, or inactivated, through exposure to heat or chemicals such as formaldehyde 3. Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques. Live vaccines maintain their replicative ability.] |
|
Influenza B virus B/Massachusetts/2/2012 antigen (MDCK cell derived, propiolactone inactivated)
|
DB11000 |
[A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen". This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. Upon re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it was previously exposed to.
There are two basic types of vaccines available: inactivated influenza vaccine (IIV) and live attenuated influenza vaccine (LAIV). Inactivated vaccines contain a virus particle that has been grown in media and then subsequently killed, or inactivated, through exposure to heat or chemicals such as formaldehyde 3. Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques. Live vaccines maintain their replicative ability.] |
|
NP-G2-044
|
DB14995 |
[NP-G2-044 is under investigation in clinical trial NCT03199586 (Phase 1 Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Solid Tumors (Including Lymphoma)).] |
|
Milataxel
|
DB12334 |
[Milataxel has been used in trials studying the treatment of Mesothelioma.] |
|
Fluanisone
|
DB13665 |
|
|
Olorinab
|
DB14998 |
[Olorinab is under investigation in clinical trial NCT03155945 (Tolerability, Pharmacokinetics, and Efficacy of APD371 in Subjects With Crohn's Disease Experiencing Abdominal Pain).] |
|
Tiemonium iodide
|
DB13666 |
|
|
Tanezumab
|
DB12335 |
[Tanezumab has been investigated for the treatment of Osteoarthritis, Knee and Neuralgia, Postherpetic.] |
|
Cefozopran
|
DB13667 |
|
|
GDC-0917
|
DB12336 |
[CUDC-427 has been used in trials studying the treatment of LYMPHOMA and Solid Cancers.] |
|
Pateclizumab
|
DB14997 |
[Pateclizumab is under investigation in clinical trial NCT01225393 (A Study to Evaluate the Efficacy and Safety of MLTA3698A in Combination With a Disease-Modifying Anti-Rheumatic Drug (DMARD) Compared With Adalimumab in Combination With a DMARD in Patients With Active Rheumatoid Arthritis).] |
|
Ulmus parvifolia pollen
|
DB11005 |
[Ulmus parvifolia pollen is the pollen of the Ulmus parvifolia plant. Ulmus parvifolia pollen is mainly used in allergenic testing.] |
|
Propicillin
|
DB13660 |
|
|
Pegunigalsidase alfa
|
DB14992 |
[Pegunigalsidase alfa is under investigation in clinical trial NCT02921620 (Study to Evaluate the Safety and EffIcacy of PRX-102 on Gastrointestinal Symptoms in Naïve Fabry Disease).] |
|
Nomacopan
|
DB14991 |
[Nomacopan is under investigation in clinical trial NCT03427060 (Coversin in PNH in Patients With Resistance to Eculizumab Due to Complement C5 Polymorphisms).] |
|
Betula pendula pollen
|
DB11004 |
[Betula pendula pollen allergenic extract is used in allergenic testing.] |
|
Blisibimod
|
DB12330 |
[Blisibimod has been used in trials studying the treatment of IgA Nephropathy, Microscopic Polyangiitis, Systemic Lupus Erythematosus, and Granulomatosis With Polyangiitis.] |
|
Niridazole
|
DB13661 |
|
|
Anthrax vaccine
|
DB11003 |
[Anthrax vaccine is a vaccine used for the pre- or post-exposure prophylaxis of disease in at high risk of, suspected or confirmed exposure to *Bacillus anthracis*. It is subcutaneously or intramuscularly administered. It is derived from cell-free filtrates of microaerophilic cultures of an avirulent, nonencapsulated strain of Bacillus anthracis which are grown in a chemically defined protein-free medium [FDA Label].] |
|
Hexapropymate
|
DB13662 |
|
